921 related articles for article (PubMed ID: 28373196)
1. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.
Tsuge M; Uchida T; Hiraga N; Kan H; Makokha GN; Abe-Chayama H; Miki D; Imamura M; Ochi H; Hayes CN; Shimozono R; Iwamura T; Narumi H; Suzuki T; Kainoh M; Taniguchi T; Chayama K
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373196
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection.
Klumpp K; Shimada T; Allweiss L; Volz T; Lütgehetmann M; Hartman G; Flores OA; Lam AM; Dandri M
Gastroenterology; 2018 Feb; 154(3):652-662.e8. PubMed ID: 29079518
[TBL] [Abstract][Full Text] [Related]
3. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.
Uchida T; Imamura M; Hayes CN; Hiraga N; Kan H; Tsuge M; Abe-Chayama H; Zhang Y; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696237
[TBL] [Abstract][Full Text] [Related]
4. Latest developments in the treatment of hepatitis B.
Dandri M; Petersen J
Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
[TBL] [Abstract][Full Text] [Related]
5. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
6. Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a (40 kda; PEGASYS).
Chan HL; Wong VW; Chim AM; Wong GL; Chan HY; Sung JJ
Antivir Ther; 2008; 13(4):555-62. PubMed ID: 18672534
[TBL] [Abstract][Full Text] [Related]
7. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
Cai Q; Chen F; Shao X; Zhang X; Zhao Z; Gao Z
Antivir Ther; 2015; 20(2):217-24. PubMed ID: 25138110
[TBL] [Abstract][Full Text] [Related]
8. The response to interferon is influenced by hepatitis B virus genotype in vitro and in vivo.
Zhang Y; Wu Y; Ye S; Wang T; Zhao R; Chen F; Abe K; Jin X
Virus Res; 2013 Jan; 171(1):65-70. PubMed ID: 23123214
[TBL] [Abstract][Full Text] [Related]
9. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.
Boglione L; Cariti G; Di Perri G; D'Avolio A
J Med Virol; 2016 Nov; 88(11):1953-9. PubMed ID: 27017932
[TBL] [Abstract][Full Text] [Related]
10. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
[TBL] [Abstract][Full Text] [Related]
11. Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection.
Han M; Li Y; Wu W; Zhang Y; Yan W; Luo X; Ning Q
Antiviral Res; 2017 Nov; 147():75-85. PubMed ID: 28988797
[TBL] [Abstract][Full Text] [Related]
12. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy.
Colombatto P; Civitano L; Bizzarri R; Oliveri F; Choudhury S; Gieschke R; Bonino F; Brunetto MR;
Antivir Ther; 2006; 11(2):197-212. PubMed ID: 16640101
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
Jansen L; Kootstra NA; van Dort KA; Takkenberg RB; Reesink HW; Zaaijer HL
J Infect Dis; 2016 Jan; 213(2):224-32. PubMed ID: 26216905
[TBL] [Abstract][Full Text] [Related]
14. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.
Wursthorn K; Lutgehetmann M; Dandri M; Volz T; Buggisch P; Zollner B; Longerich T; Schirmacher P; Metzler F; Zankel M; Fischer C; Currie G; Brosgart C; Petersen J
Hepatology; 2006 Sep; 44(3):675-84. PubMed ID: 16941693
[TBL] [Abstract][Full Text] [Related]
15. Anti-HBV drugs suppress the growth of HBV-related hepatoma cells via down-regulation of hepatitis B virus X protein.
Zhang S; Gao S; Zhao M; Liu Y; Bu Y; Jiang Q; Zhao Q; Ye L; Zhang X
Cancer Lett; 2017 Apr; 392():94-104. PubMed ID: 28192212
[TBL] [Abstract][Full Text] [Related]
16. CD56
Shi A; Zhang X; Xiao F; Zhu L; Yan W; Han M; Luo X; Chen T; Ning Q
J Viral Hepat; 2018 Nov; 25(11):1352-1362. PubMed ID: 29888839
[TBL] [Abstract][Full Text] [Related]
17. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?
Kao JH
Liver Int; 2014 Feb; 34 Suppl 1():112-9. PubMed ID: 24373087
[TBL] [Abstract][Full Text] [Related]
18. Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?
Viganò M; Invernizzi F; Lampertico P
Liver Int; 2015 Jan; 35 Suppl 1():107-13. PubMed ID: 25529095
[TBL] [Abstract][Full Text] [Related]
19. Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication.
Wang YX; Niklasch M; Liu T; Wang Y; Shi B; Yuan W; Baumert TF; Yuan Z; Tong S; Nassal M; Wen YM
J Hepatol; 2020 May; 72(5):865-876. PubMed ID: 31863794
[TBL] [Abstract][Full Text] [Related]
20. The effect of peginterferon alpha-2a vs. interferon alpha-2a on intrahepatic covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients.
Liu S; Zheng H; Huang Y; Li B; Dong Z
Clin Res Hepatol Gastroenterol; 2016 Jun; 40(3):304-308. PubMed ID: 26382279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
